Floatz logo

Irinotecan

Neoplasms, Glandular and Epithelial

Xiaoxiang ChenSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Neoplasms, Glandular and Epithelial cohort.

Asset / SponsorPhaseRating
Sorafenib
Shandong Cancer Hospital and Institute
Phase 3BB
Epirubicin
Sheba Medical Center
Phase 2B
Cyclophosphamide
Sheba Medical Center
Phase 2B
Pembrolizumab
Sheba Medical Center
Phase 2B
Linifanib
Abbott
Phase 3B

View all 22 →

Same molecule, other indications

Irinotecan is also rated in:

rectal cancerDormant
BBB
Indicative ·
78 / 100
View asset →
exocrine pancreatic carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
Peritoneal NeoplasmsDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →